Athersys (ATHX) MultiStem Phase 2 Missed Primary, Secondary Endpoints
Tweet Send to a Friend
Athersys (NASDAQ: ATHX) announced interim results from its exploratory Phase 2 clinical study of the intravenous administration of MultiStem cell ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE